CMRX $8.54 intraday (Chimerix, Inc., NASDAQ) 12 Mar 2026: watch $6.67 support

CMRX stock is trading at $8.54 intraday on the NASDAQ in the United States and shows a short-term setup for an oversold bounce after recent volatile swings. Volume sits at 2,552,273.00, below the 50-day average, suggesting limited selling pressure today. Traders watching an oversold bounce should focus on the $6.67 50-day average and the $2.75 200-day average as support levels. This intraday note connects fundamentals, technicals and Meyka AI signals to outline a practical rebound trade plan.

Intraday technical setup for CMRX stock

CMRX stock opened at $8.54 and is holding near the session price with day high and low both at $8.54, suggesting a tight intraday range. The 50-day average is $6.67 and the 200-day average is $2.75, giving defined pullback targets for an oversold bounce entry. Relative volume is 0.63, so a genuine bounce will need a pickup toward the average volume 4,049,203.00 to confirm conviction.

Catalysts and CMRX stock news drivers

Chimerix, Inc. (CMRX) runs clinical-stage programs (ONC201, ONC206, ONC212) and an approved product TEMBEXA, which keep newsflow linked to trial updates and regulatory milestones. No fresh regulatory headlines are live intraday, so short-term moves will likely be technical or driven by biotech sector sentiment. For official company updates see Chimerix investor site and the company LinkedIn page for filings and presentations source.

Fundamentals and valuation for CMRX stock

Chimerix shows a market cap of $801,084,452.00, EPS of -0.99 and a PE of -8.63, reflecting current negative earnings. Cash per share is 1.46, book value per share is 1.35, and the current ratio is 5.70, which supports short-term liquidity. High R&D spend (about 449.42% of revenue TTM) keeps upside tied to clinical progress rather than near-term revenue growth.

Meyka AI grade and short-term CMRX stock forecast

Meyka AI rates CMRX with a score out of 100: 67 (Grade B) with a suggestion to HOLD. This grade factors in S&P 500 and sector comparisons, financial growth, key metrics, analyst consensus and forecasts. Meyka AI’s forecast model projects a 1-year price of $7.96, 3-year $12.87, and 5-year $17.76, compared with the current price $8.54 — forecasts are model-based projections and not guarantees.

Risk, trade plan and CMRX stock strategy

For an oversold bounce trade, risk control is critical: consider entries near the 50-day average $6.67 and use a stop below the 200-day average $2.75 for larger position sizing. Short-term targets: initial partial profit at the yearly forecast $7.96, a medium target at $12.87, and a stretch target at $17.76. Limit size to a small biotech allocation due to binary clinical risk.

Sector context and liquidity for CMRX stock

CMRX operates in US Biotechnology within Healthcare, where sector flows strongly affect small-cap biotechs. Average volume 4,049,203.00 and current outstanding shares 93,803,800.00 mean intraday liquidity is reasonable but can gap on news. Monitor broader biotech ETFs and FDA calendar for correlated moves that could trigger a cleaner oversold bounce.

Final Thoughts

Key takeaways for CMRX stock: the intraday price is $8.54 on NASDAQ and technical structure supports an oversold-bounce approach with clear support at the 50-day average $6.67 and long-term support at the 200-day average $2.75. Meyka AI’s forecast model projects $7.96 at 1 year, implying a downside of -6.81% from today, but a 3-year projection to $12.87 implies upside of 50.68% and a 5-year projection to $17.76 implies upside of 108.03%. Meyka AI rates CMRX with a score of 67 out of 100 (Grade B, suggestion HOLD), reflecting mixed fundamentals, strong liquidity ratios and binary clinical risk. For an oversold-bounce trade we recommend targeting a scale-in near $6.67, light sizing, a stop beneath $2.75 for capital preservation, and partial profit-taking near $7.96. All forecasts are model-based and not guarantees; use position sizing and stop-loss discipline when trading biotech volatility. For company filings and investor materials see the Chimerix site source and follow the company LinkedIn updates for primary releases.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.